Fate Therapeutics(NASDAQ:FATE)报告2024年第四季度每股亏损$(0.44)，未能达到分析师一致预期的$(0.43)，低于预期2.33%。与去年同期每股亏损$(0.45)相比，增长了2.22%。公司报告季度销售额为$1.860，未达到分析师一致预期的$1.416百万，低于预期100%。与去年同期销售额$1.676百万相比，下降了100%。

以上内容来自Benzinga Earnings专栏，原文如下：

Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.43) by 2.33 percent. This is a 2.22 percent increase over losses of $(0.45) per share from the same period last year. The company reported quarterly sales of $1.860 which missed the analyst consensus estimate of $1.416 million by 100.00 percent. This is a 100.00 percent decrease over sales of $1.676 million the same period last year.